


Reasons for Switching on 1st Line

% of Eyes Tx on 1st Line, and considering switching



↑↓ Statistically significant at 95% confidence level vs. Q1 2020
 ↑↓ Statistically significant at 95% confidence level vs. Q4 2019
 *Messages <5% across indications not shown
 When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves




Maru/ - Confidential

DR w/o DME Tracking– First Line of Therapy Stated Product Usage

DR w/o DME Diagnosed, Anti-VEGF 1st Line of Therapy
Projected Market Share Allocation by Product – Total Market
(Q2 2020 wave n=201 retina specialists; 25,870 eyes)

◆ AVASTIN
 ✕ Brolucizumab
 ◆ LUCENTIS
 ✱ Avastin as bridge for EYLEA
 ◆ Avastin bridge for LUCENTIS
 ◆ EYLEA
 ◆ Avastin bridge for Brolucizumab



Combination of Mild NPDR / Moderate NPDR / Severe NPDR / PDR eyes.


Source: Q2 2020 ATU Study (n=201 retina specialists)



DR w/o DME Tracking– Second Line of Therapy Stated Product Usage

DR w/o DME Diagnosed, Anti-VEGF 2nd Line of Therapy
Projected Market Share Allocation by Product – Total Market
(Q2 2020 wave n=201 retina specialists; 6,528 eyes)

◆ AVASTIN ■ LUCENTIS ▲ EYLEA ✕ Brolucizumab



Combination of Mild NPDR / Moderate NPDR / Severe NPDR / PDR eyes.


Source: Q2 2020 ATU Study (n=201 retina specialists)



DR w/o DME Tracking– Third Line of Therapy Stated Product Usage

DR w/o DME Diagnosed, Anti-VEGF 3rd Line of Therapy
Projected Market Share Allocation by Product – Total Market
(Q2 2020 wave n=201 retina specialists; 3,693 eyes)

—◆— AVASTIN —■— LUCENTIS —▲— EYLEA —X— Brolucizumab




Combination of Mild NPDR / Moderate NPDR / Severe NPDR / PDR eyes.
Source: Q2 2020 ATU Study (n=201 retina specialists)



Line of Therapy By DR w/out DME Severity

Mild Non-Proliferative, Anti-VEGF Treated Eyes


1st, 2nd, 3rd+ Line of Anti-VEGF Therapy
(n=3,949 eyes)



■ 1st Line Therapy ■ 2nd Line Therapy ■ 3rd+ Line Therapy

Moderate Non-Proliferative, Anti-VEGF Treated Eyes


1st, 2nd, 3rd+ Line of Anti-VEGF Therapy
(n=7,399 eyes)



■ 1st Line Therapy ■ 2nd Line Therapy ■ 3rd+ Line Therapy

Severe Non-Proliferative, Anti-VEGF Treated Eyes


1st, 2nd, 3rd+ Line of Anti-VEGF Therapy
(n=11,605 eyes)



■ 1st Line Therapy ■ 2nd Line Therapy ■ 3rd+ Line Therapy

Proliferative, Anti-VEGF Treated Eyes

1st, 2nd, 3rd+ Line of Anti-VEGF Therapy
(n=13,138 eyes)




■ 1st Line Therapy ■ 2nd Line Therapy ■ 3rd+ Line Therapy

1st Line Market Share by DR w/out DME Severity


Mild Non-Proliferative Initial Therapy (1st line)

Share Allocation: 1st Line Anti-VEGF Therapy
(n=2,823 eyes)




Moderate Non-Proliferative Initial Therapy (1st line)

Share Allocation: 1st Line Anti-VEGF Therapy
(n=5,667 eyes)




Severe Non-Proliferative Initial Therapy (1st line)

Share Allocation: 1st Line Anti-VEGF Therapy
(n=8,346 eyes)



Proliferative Initial Therapy (1st line)

Share Allocation: 1st Line Anti-VEGF Therapy
(n=9,035 eyes)



↑↓ Statistically significant at 95% confidence level vs. Q1 2020

Maru/ - Confidential


When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves




85

2nd Line Market Share by DR w/out DME Severity


Mild Non-Proliferative 2nd Line Therapy
Share Allocation: 2nd Line Anti-VEGF Therapy
(n=699 eyes)




Moderate Non-Proliferative 2nd Line Therapy
Share Allocation: 2nd Line Anti-VEGF Therapy
(n=1,229 eyes)



Severe Non-Proliferative 2nd Line Therapy
Share Allocation: 2nd Line Anti-VEGF Therapy
(n=2,024 eyes)




Proliferative 2nd Line Therapy
Share Allocation: 2nd Line Anti-VEGF Therapy
(n=2,577 eyes)




3rd Line Market Share by DR w/out DME Severity


Mild Non-Proliferative 3rd Line Therapy or Later
Share Allocation: 3rd+ Line Anti-VEGF Therapy
(n=427 eyes)




Moderate Non-Proliferative 3rd Line Therapy
Share Allocation: 3rd+ Line Anti-VEGF Therapy
(n=504 eyes)



Severe Non-Proliferative 3rd Line Therapy
Share Allocation: 3rd+ Line Anti-VEGF Therapy
(n=1,235 eyes)



Proliferative 3rd Line Therapy
Share Allocation: 3rd+ Line Anti-VEGF Therapy
(n=1,527 eyes)



↑↓ Statistically significant at 95% confidence level vs. Q1 2020

↑↓ Statistically significant at 95% confidence level vs. Q4 2019


When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves

Maru/ - Confidential

Switching Behavior by DR w/out DME Severity


% of 1st Line Mild Non-Proliferative

Eyes Considered for Switching




% of 1st Line Moderate Non-Proliferative

Eyes Considered for Switching




% of 1st Line Severe Non-Proliferative

Eyes Considered for Switching



% of 1st Line Proliferative Eyes

Considered for Switching



↑↓ Statistically significant at 95% confidence level vs. Q1 2020

↑↓ Statistically significant at 95% confidence level vs. Q4 2019


When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves

Maru/ - Confidential

DR w/out DME – Reasons for Switching on 1st Line

% of Eyes Tx on 1st Line, and considering switching

(By Eye Severity)



↑↓ Statistically significant at 95% confidence level vs. Q1 2020

↑↓ Statistically significant at 95% confidence level vs. Q4 2019

*Messages <11% across indications not shown

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves

Maru/ - Confidential




ANTI-VEGF DOSING SUMMARY




Wet AMD Approved Dosing Schedule

% Aware of Approved Dosing Schedule For EYLEA...
After Initial Dosing
(Unaided Awareness)



% Aware of Approved Dosing Schedule For...
After Initial Dosing
(Aided Awareness)




Source: Q2 2020 ATU Study (n=201 retina specialists)

↑↓ Statistically significant at 95% confidence level vs. Q1 2020

Wet AMD Dosing Update

Overall Dosing Interval in # Weeks
Projected % Treated Eyes Receiving Dosing Schedule*




*Ongoing, following initiation of therapy
Source: Q2 2020 ATU Study (n=201 retina specialists)




DME Approved Dosing Schedule

% Aware of Approved Dosing Schedule For...
After Initial Dosing
(Unaided Awareness)



% Aware of Approved Dosing Schedule For...
After Initial Dosing
(Aided Awareness)




Source: Q2 2020 ATU Study (n=200 retina specialists)

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves



DME Dosing Update

Overall Dosing Interval in # Weeks
Projected % Treated Eyes Receiving Dosing Schedule*



*Ongoing, following initiation of therapy

Source: Q2 2020 ATU Study (n=200 retina specialists)


↑↓ Statistically significant at 95% confidence level vs. Q4 2019

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves




MEfRVO Approved Dosing Schedule

% Aware of Approved Dosing Schedule For...
After Initial Dosing
(Unaided Awareness)



% Aware of Approved Dosing Schedule For...
After Initial Dosing
(Aided Awareness)



Source: Q2 2020 ATU Study (n=100 retina specialists)

↑↓ Statistically significant at 95% confidence level vs. Q1 2020

MEfCRVO Dosing Update

Overall Dosing Interval in # Weeks
Projected % Treated Eyes Receiving Dosing Schedule*


Mean Frequency:

Avastin: 6.3

Lucentis: 6.3

EYLEA: 8.1

Brolucizumab: 8.4



*Ongoing, following initiation of therapy

Source: Q2 2020 ATU Study (n=100 retina specialists)



MEfBRVO Dosing Update

Overall Dosing Interval in # Weeks
Projected % Treated Eyes Receiving Dosing Schedule*


Mean Frequency:

Avastin: 5.9

Lucentis: 6.2

EYLEA: 7.7

Brolucizumab: 8.7




*Ongoing, following initiation of therapy
Source: Q2 2020 ATU Study (n=100 retina specialists)




DR w/out DME Approved Dosing Schedule

% Aware of Approved Dosing Schedule For...
After Initial Dosing
(Unaided Awareness)




% Aware of Approved Dosing Schedule For...
After Initial Dosing
(Aided Awareness)



Source: Q2 2020 ATU Study (n=201 retina specialists)

DR w/out DME Dosing Update



Source: Q2 2020 ATU Study (n=201 retina specialists)

Statistically significant at 95% confidence level vs. Q4 2019

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves






Patient Requests



EYLEA Patient Requests



Source: Q2 2020 ATU Study (n=201 retina specialists reporting Wet AMD, n=200 retina specialists reporting DME, n=100 retina specialists reporting MEfRVO, n=201 retina specialists reporting DR No DME; 166,174 eyes total)

↑↓ Statistically significant at 95% confidence level vs. Q1 2020


↑↓ Statistically significant at 95% confidence level vs. Q4 2019

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves




Wet AMD Patient Request


% of Patients Who Requested Specific Tx...
(n=103,408 Wet AMD patients)




% of MDs Likely to Grant Specific Requested Tx...



% of Patients Who Requested Asked for... (Ever)
(n=15,743 Wet AMD patients)



% of Requests Honored
(n= varies by Tx)



Source: Q2 2020 ATU Study (n=201 retina specialists) *N/A: unable to show due to small MD base < 15
 ↑↓ Statistically significant at 95% confidence level vs. Q1 2020



Maru/ - Confidential

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves

Wet AMD Patient Request

Primary Reason for NOT Honoring Request

(Patients where request was not honored)	EYLEA (n=2099)	Avastin (n=1461)	Lucentis (n=1582)	Laser (n=1614)	Brolucizumab (n=1307)	Iluvien (n=1237)	Ozurdex (n=1142)
Clinical appropriateness	33%	18% ↓ (36%)	27%	27% ↓ (43%)	5%	18%	25%
Cost to patient	20%	14%	18%	14%	6%	14%	14%
Cost/Risk to practice	13%	20% ↓ (36%)	15%	18%	5%	17%	15%
Safety	12%	15%	16%	14%	6%	17%	16%
Patient compliance	11%	20%	12%	16%	4%	17%	13%
Stocking	11%	13%	12%	11%	4%	17%	15%
Other	0%	0%	0%	1%	0%	0%	1%

Source: Q2 2020 ATU Study (n=201 retina specialists)

↑↓ Statistically significant at 95% confidence level vs. Q1 2020


↑↓ Statistically significant at 95% confidence level vs. Q4 2019

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves




DME Patient Request


% of Patients Who Requested Specific Tx...
(n=67,294 DME patients)




% of MDs Likely to Grant Specific Requested Tx...



% of Patients Who Requested Asked for... (Ever)
(n=4,449 DME patients)



% of Requests Honored
(n= varies by Tx)



Source: Q2 2020 ATU Study (n=200 retina specialists) *N/A: unable to show due to small MD base < 15

↑↓ Statistically significant at 95% confidence level vs. Q4 2019

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves



Maru/ - Confidential

DME Primary Reason NOT Honoring Request

Primary Reason for NOT Honoring Request

Reasons where request was not honored	EYLEA (n=643)	Lucentis (n=408)	Laser (n=385)	Avastin (n=221)	Ozurdex (n=269)	Brolucizumab (n=202)
Clinical appropriateness	45% ↑ (33%)	34%	30% ↓ (71%)	24%	49% ↑ (23%)	27%
Cost to patient	28%	21%	18%	9%	10%	16%
Cost/Risk to practice	8%	11%	17%	10%	5%	7%
Safety	7%	10% ↓ (30%)	11%	15%	14%	15% ↓ (49%)
Stocking	7%	14%	12%	21%	11%	28%
Patient compliance	5%	9%	13%	17%	10%	6%
Other	1%	2%	0%	4%	0%	0%

*Iluvien not shown due to MD base size <15

Source: Q2 2020 ATU Study (n=200 retina specialists)

↑↓ Statistically significant at 95% confidence level vs. Q1 2020




Maru/ - Confidential


When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves

MEfCRVO Patient Request


% of Patients Who Requested Specific Tx...
(n=9,472 MEfCRVO patients)




% of MDs Likely to Grant Specific Requested Tx...



% of Patients Who Requested Asked for... (Ever)
(n=793 MEfCRVO patients)



% of Requests Honored
(n= varies by Tx)



Source: Q1 2020 ATU Study (n=100 retina specialists) *N/A: unable to show due to small MD base < 15
 ↑↓ Statistically significant at 95% confidence level vs. Q1 2020



Maru/ - Confidential

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves

MEfCRVO Primary Reason NOT Honoring Request

Primary Reason for NOT Honoring Request

	EYLEA (n=107)	Lucentis (n=63)
Clinical appropriateness	30% ↓ (63%)	17%
Cost to patient	26%	26%
Cost/Risk to practice	15%	28%
Safety	12%	9%
Patient compliance	10%	13%
Stocking	7%	7%

*Avastin, Brolucizumab, Laser, Ozurdex, Illuvien not shown due to MD base size <15

Source: Q2 2020 ATU Study (n=100 retina specialists)

↑↓ Statistically significant at 95% confidence level vs. Q1 2020


Maru/ - Confidential

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves




MEfBRVO Patient Request


% of Patients Who Requested Specific Tx...
(n=11,666 MEfBRVO patients)




% of MDs Likely to Grant Specific Requested Tx...



% of Patients Who Requested Asked for... (Ever)
(n=896 MEfBRVO patients)



% of Requests Honored
(n= varies by Tx)



Source: Q2 2020 ATU Study (n=100 retina specialists) *N/A: unable to show due to small MD base < 15

↑↓ Statistically significant at 95% confidence level vs. Q1 2020

↑↓ Statistically significant at 95% confidence level vs. Q4 2019

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves



Maru/ - Confidential

MEfBRVO Primary Reason NOT Honoring Request

Primary Reason for NOT Honoring Request

	EYLEA (n=132)
Clinical appropriateness	35%
Cost to patient	17%
Stocking	14%
Cost/Risk to practice	14%
Patient compliance	12%
Safety	8%


**Avastin, Lucentis, Brolucizumab, Laser, Ozurdex, Iluvien not shown due to MD base size <15*

Source: Q2 2020 ATU Study (n=100 retina specialists)



DR w/out DME Patient Request


% of Patients Who Requested Specific Tx...
(n=73,097 DR No DME patients)




% of MDs Likely to Grant Specific Requested Tx...
(n=201)
47%



% of Patients Who Requested Asked for... (Ever)
(n=4,311 DR No DME patients)



% of Requests Honored
(n= varies by Tx)



Source: Q2 2020 ATU Study (n=201 retina specialists)



DR w/out DME Primary Reason NOT Honoring Request

Primary Reason for NOT Honoring Request

	EYLEA (n=730)	Lucentis (n=481)	Avastin (n=356)	PRP (n=390)	Brolucizumab (n=364)
Clinical appropriateness	38%	48%	18%	24%↓ (55%)	37%
Cost to patient	22%	14%	14%	7%	14%
Cost/Risk to practice	13%	13%	9%↑ (1%)	6%	21%
Stocking	9%	7%	8%	6%	5%
Patient compliance	8%	9%	40%	48%	6%
Safety	7%	8%	10%	7%	9%
Other	2%	1%	1%	1%	7%

Source: Q2 2020 ATU Study (n=201 retina specialists)

↑↓ Statistically significant at 95% confidence level vs. Q1 2020






Brolucizumab in the News




Brolucizumab in the News

% Heard Any New Info About Brolucizumab...



% Heard about Brolucizumab....



Source: Q2 2020 ATU Study (n=201 retina specialists reporting wet AMD)


↑↓ Statistically significant at 95% confidence level vs. Q1 2020

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves




Impact of AEs

Impact of Retinal Vasculitis on Rx



Acceptable level of occlusive retinal vasculitis that would NOT affect Brolucizumab usage....



Source: Q2 2020 ATU Study (n=141 retina specialists heard about RV)

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves






Sampling



EYLEA Sample Supply

% Felt Past 3 Month EYLEA Sample Supply Was...



Source: Q2 2020 ATU Study (n=201 retina specialists reporting Wet AMD, n=200 retina specialists reporting DME, n=100 retina specialists reporting MEfRVO)


↑↓ Statistically significant at 95% confidence level vs. Q1 2020

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves



Lucentis Sample Supply

% Felt Past 3 Month LUCENTIS Sample Supply Was...



Source: Q2 2020 ATU Study (n=201 retina specialists reporting Wet AMD, n=200 retina specialists reporting DME, n=100 retina specialists reporting MEfRVO)

↑↓ Statistically significant at 95% confidence level vs. Q1 2020


↑↓ Statistically significant at 95% confidence level vs. Q4 2019

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves



Brolucizumab Sample Supply

% Felt Past 3 Month BROLUCIZUMAB Sample Supply Was...



Source: Q2 2020 ATU Study (n=201 retina specialists reporting Wet AMD, n=200 retina specialists reporting DME, n=100 retina specialists reporting MEfRVO)

↑↓ Statistically significant at 95% confidence level vs. Q4 2019


When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves




DR w/out DME Sample Supply

% Felt Past 3 Month **EYLEA** Sample Supply Was...

EYLEA Sample Supply




% Feel Low Sample Supply Impacts...
(Top 2 Box, 5 pt. Scale)




% Felt Past 3 Month **Lucentis** Sample Supply Was...

Lucentis Sample Supply




% Feel Low Sample Supply Impacts...
(Top 2 Box, 5 pt. Scale)




% Felt Past 3 Month **Avastin** Sample Supply Was...

Avastin Sample Supply




% Feel Low Sample Supply Impacts...
(Top 2 Box, 5 pt. Scale)




% Felt Past 3 Month **Brolucizumab** Sample Supply Was...

Avastin Sample Supply



% Feel Low Sample Supply Impacts...
(Top 2 Box, 5 pt. Scale)



Source: Q2 2020 ATU Study (n=202 retina specialists reporting Wet AMD, n=200 retina specialists reporting DME, n=100 retina specialists reporting MEfRVO, n=201 retina specialists reporting DR No DME)





Appendix









Brand Funnel





Anti-VEGF Treatment Funnel



Maru/ - Confidential

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves

DR w/out DME Anti-VEGF Treatment




Source: ATU Study (n=201 retina specialists; n=108,472 DR w/o DME Eyes)

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves


Maru/ - Confidential

DR w/out DME Anti-VEGF Treatment Funnel – By Eye Severity


Mild Non-Proliferative Eyes
(n=36,326)




Moderate Non-Proliferative Eyes
(n=30,159)



Severe Non-Proliferative Eyes
(n=22,206)



Proliferative Eyes
(n=19,781)




Maru/ - Confidential

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves

Primary Reason Not Receiving Treatment

% of Eyes Eligible for Tx, Not Receiving Primary Reason
(By indication)



Source: Q2 2020 ATU Study (n=201 retina specialists reporting Wet AMD, n=200 retina specialists reporting DME, n=100 retina specialists reporting MEfRVO; 166,174 eyes total)

↑↓ Statistically significant at 95% confidence level vs. Q1 2020


↑↓ Statistically significant at 95% confidence level vs. Q4 2019

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves

125

DR w/o DME - Primary Reason Not Receiving Treatment

% of Eyes Eligible for Tx, Not Receiving Primary Reason
(By indication)



↑↓ Statistically significant at 95% confidence level vs. Q1 2020

Source: Q2 2020 ATU Study (n=201 retina specialists)

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves






Brand Perceptions Changes & Share Impact



Change in Brand Perceptions

(Past 3 months)



Source: Q2 2020 ATU Study (n=201 retina specialists reporting Wet AMD, n=200 retina specialists reporting DME, n=100 retina specialists reporting MEFRVO, n=201 retina specialists reporting DR No DME; 166,174 eyes total)

↑↓ Statistically significant at 95% confidence level vs. Q1 2020

↑↓ Statistically significant at 95% confidence level vs. Q4 2019


When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves

Significantly more positive
Somewhat more positive
No change
Somewhat more negative
Significantly more negative


Maru/ - Confidential

Wet AMD Market Share by Change in Perceptions of EYLEA

Total Q2 Share



Wet AMD Market Share
(by Change in Perception of EYLEA Over the Past 3 Months)




Source: Q2 2020 ATU Study (n=201 retina specialists)



DME Market Share by Change in Perceptions of EYLEA

Total Q2 Share




DME Market Share
(by Change in Perception of EYLEA Over the Past 3 Months)



More Positive



No Change



More Negative*



*Caution: Small base size


Source: Q2 2020 ATU Study (n=200 retina specialists)



MEfRVO Market Share by Change in Perceptions of EYLEA

MEfRVO Market Share

(by Change in Perception of EYLEA Over the Past 3 Months)



Source: Q2 2020 ATU Study (n=100 retina specialists)




Maru/ - Confidential

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves


131

DR w/o DME Market Share by Change in Perceptions of EYLEA

Total Share



DR w/o DME Market Share
(by Change in Perception of EYLEA Over the Past 3 Months)



Source: Q2 2020 ATU Study (n=201 retina specialists)






DR w/o DME Appendix



DR w/out DME – Patients and # of Eyes



Source: Q2 2020 ATU Study (n=201 retina specialists)


↑↓ Statistically significant at 95% confidence level vs. Q1 2020

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves




DR w/out DME – Referrals

% of DR w/out DME Patients Referred from another HCP



% of DR w/out DME Patients Referred from...




Source: Q2 2020 ATU Study (n=201 retina specialists)




Types and Symptoms of DR w/out DME Eyes

% of DR w/out DME Patients at Time of Evaluation...




% Use DRSS when evaluating DR Pts.
(Always/Most of the time)




Source: Q2 2020 ATU Study (n=201 retina specialists)

% of DR w/out DME Eyes...



DR w/out DME Treatment

% of Treated DR w/out DME Eyes Treated with...




Source: Q2 2020 ATU Study (n=201 retina specialists)




DR w/out DME Share Update – By Eye Severity

DR w/out DME, **TOTAL Anti-VEGF Treated Eyes**
Market Share Allocation


Share Allocation: **Mild Non-proliferative DR**
(n=3,949 eyes)




Share Allocation: **Moderate Non-proliferative DR**
(n=7,399 eyes)



Share Allocation: **Severe Non-proliferative DR**
(n=11,605 eyes)



Share Allocation: **Proliferative DR**
(n=13,138 eyes)



↑↓ Statistically significant at 95% confidence level vs. Q1 2020


Source: Q2 2020 ATU Study (n=201 retina specialists)

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves

Maru/ - Confidential

DR w/out DME Therapies

DR w/no DME, TOTAL Anti-VEGF Treated Eyes
Market Share Allocation



Source: Q2 2020 ATU Study (n=201 retina specialists)

↑↓ Statistically significant at 95% confidence level vs. Q1 2020

Maru/ - Confidential

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves




Stated Product Usage by Eye Type



DR w/out DME Treatment Type – Newly Treated Eyes

% of NEW DR w/out DME Eyes Treated with...




Source: Q2 2020 ATU Study (n=201 retina specialists)



DR w/out DME Treatment Type – Newly Treated Eyes

DR w/no DME, **NEW Anti-VEGF Treated** Eyes
Market Share Allocation



Source: Q2 2020 ATU Study (n=201 retina specialists)


↑↓ Statistically significant at 95% confidence level vs. Q1 2020

Maru/ - Confidential

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves

DR w/out DME Treatment Type – Continuing Eyes

% of Continuing DR w/out DME Eyes Treated with...



Source: Q2 2020 ATU Study (n=201 retina specialists)


↑↓ Statistically significant at 95% confidence level vs. Q1 2020

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves



DR w/out DME Treatment Type – Continuing Eyes

DR w/no DME, CONTINUING Anti-VEGF Treated Eyes
Market Share Allocation



Source: Q2 2020 ATU Study (n=201 retina specialists)


↑↓ Statistically significant at 95% confidence level vs. Q1 2020

Maru/ - Confidential

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves

DR w/out DME Treatment Type – Switched Eyes

% of Switched DR w/out DME Eyes Treated with...



Source: Q2 2020 ATU Study (n=201 retina specialists)


↑↓ Statistically significant at 95% confidence level vs. Q1 2020

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves



DR w/out DME Treatment Type – Switched Eyes

DR w/no DME, SWITCHED Anti-VEGF Treated Eyes
Market Share Allocation



Source: Q2 2020 ATU Study (n=201 retina specialists)

↑↓ Statistically significant at 95% confidence level vs. Q1 2020

Maru/ - Confidential

When arrows are not present, share trends are directional and not significant; sample not entirely stable across waves



Methodology



Methodology:

	Retina Specialists	Fieldwork	LOI
Wet AMD	201	6/16 – 6/26 2020	25 minutes
DME	200	6/11 – 6/24 2020	20 minutes
MEfRVO	100	6/10 – 6/22 2020	24 minutes
DR w/out DME	201	6/11– 6/25 2020	29 minutes

spent in patient care, and 2-39 years in practice, give 50+ injections typical month

- Treat 75+ Wet AMD patients
- Treat 50+ DME patients
- Treat 50+ MEfRVO patients
- Treat 50+ DR w/out DME patients

**Sample weighted to match region distribution of Regeneron-provided sample list.*



Significance Testing:

- Significance testing was conducted at the **95% confidence level** using the MD base size. Statistically significant differences indicated for:

↑ Significant increase vs. Q1 2020

↓ Significant decrease vs. Q1 2020

↑ Significant increase vs. Q4 2019

↓ Significant decrease vs. Q4 2019

- Significance testing example:

